title: Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?
authors.affiliation: Oncology Unit, SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy. vittoriofusco1@tin.it.
authors.forename: Vittorio
authors.identifier: 0000-0003-0263-9820
authors.initials: V
authors.lastname: Fusco
authors.affiliation: Unit of Maxillofacial Surgery, Department of Neurosciences - DNS, University of Padua, Padua, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Bedogni
authors.affiliation: Bristol Cancer Institute, University Hospitals Bristol NHS, Bristol, UK.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Addeo
authors.affiliation: Department of Surgical, Oncology and Oral Sciences - Sector of Oral Medicine, Palermo University, Palermo, Italy.
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Campisi
mesh_terms: D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw; D050071:Bone Density Conservation Agents; D000069448:Denosumab; D004164:Diphosphonates; D006801:Humans; D007571:Jaw Diseases; D009369:Neoplasms; D010020:Osteonecrosis
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab